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The fibrinolytic activity of the intravascular com-partment is a major mechanism of defense against thrombosis. It allows specific lysis of excess fibrin 
formed after vascular injury in order to restore vascular 
integrity and blood flow. Its effectiveness depends on the 
simultaneous functioning of the fibrin network as (a) a 
support of the hemostatic clot, (b) a surface for the as-
sembly of a ternary complex with plasminogen and tissue 
activator (tPA), (c) a surface for plasminogen activation 
and (d) a substrate for plasmin.1
ABSTRACT
Thrombus lysis is the consequence of a restricted number of reac-
tions localised to the surface of fibrin. A functional defect or an insuf-
ficient fibrinolytic response may lead to thrombosis with severe or 
fatal clinical consequences, e.g. myocardial infarction and ischemic 
stroke. Despite this clinical exigency and a real progress in the 
knowledge of the different components of this system (plasminogen 
and its activators, inhibitors and receptors), its functional evaluation 
still remains a challenge in haemostasis. The absolute requirement 
of a template for molecular assembly of plasminogen and its activa-
tors (tissue- and urokinase-type plasminogen activators: tPA and 
uPA) restricts the formation of plasmin and protects its activity onto 
the surface of, respectively, fibrin and cells. In contrast, plasmin and 
tPA released from the clot during its lysis are immediately neutral-
ised by their respective inhibitors a2-antiplasmin and plasminogen 
activator inhibitor 1, PAI-1). It seems therefore almost impossible 
to detect fibrinolytic activity in plasma with methods currently in 
use. Because of its unavailability, it is also impossible to measure 
the degree of fibrinolysis directly on the clot. Notwithstanding, it 
was recently discovered that circulating membrane microvesicles 
might be indicators of the fibrinolytic response to an inflammatory or 
prothrombotic process. These cell-derived fibrinolytic microvesicles 
bear at their membrane the plasminogen activators expressed by 
the parent cell: tPA from endothelial cells and uPA from leukocytes. 
These molecules are localised at the membrane surface and have 
the capacity to activate plasminogen into plasmin in situ. Moreover, 
it was recently discovered that these microvesicles might participate 
in a new mechanism of plasmin formation requiring a cross-talk be-
tween two different surfaces. In this fibrinolytic cross-talk one of the 
surfaces bear plasminogen (fibrin, extracellular matrix or platelets) 
whereas the other surface carry the plasminogen activator, typically 
leukocyte-derived microvesicles bearing uPA. These new actors 
and concepts in plasminogen activation represent hitherto unknown 
pathways in our comprehension of fibrinolysis and potential novel 
biomarkers in clinical practice. 
The tPA is synthesized and released by the endothelium 
in response to a number of stimuli.2 Released into contact 
with the clot, it binds to fibrin but can also generate plasmin 
on the endothelial surface.3 Other cellular components 
involved in thrombus formation are also involved in its 
dissolution. For instance, leukocytes that form aggregates 
with platelets release a second type of plasminogen activa-
tor: urokinase (uPA), which can, under certain conditions, 
activate plasminogen bound to fibrin.4  However, the 
activation of plasminogen by uPA occcurs primarily at 
the cell membrane.5  If the membrane of endothelial cells 
and leukocytes behave as surfaces for the production of 
plasmin, the membrane of platelets play an important role 
as a source of plasminogen within the thrombus.6 Platelets 
can also develop a regulatory activity by releasing PAI-1, 
the major inhibitor of plasminogen activators.7 
Recently, we have shown that beyond the participation 
of cells, a similar mechanism of activation of plasminogen 
was present at the membrane of microvesicles from the cell 
line HMEC-1 (human microvascular endothelial cells).8 
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Moreover, more recent studies have demonstrated the ex-
istence of a new mechanism for the formation of plasmin, 
the fibrinolytic cross-talk, requiring a first surface bearing 
plasminogen and a second suface bearing the plasminogen 
activator uPA.9 The formation of plasmin on fibrin or on the 
cell membrane is therefore built on the close relationship 
between the molecular conformation of the plasminogen 
adsorbed onto a surface and its recognition by activators 
immobilized on the same surface or on a moving surface.
These two new mechanisms, the fibrinolytic activity 
of membrane microvesicles and the fibrinolytic cross-
talk, represent new pathways for fibrinolysis. They will 
be analyzed in this review after having defined the role 
played by conformational changes of plasminogen in the 
mechanism of plasmin generation.
Plasminogen structure and conformational changes 
This 92 kDa glycoprotein consists of 791 amino acids 
(Asn791-Glu1, Glu-plasminogen) that are grouped into 
five modules called “kringle” and a catalytic region. These 
modular elements are preceded by an amino-terminal 
peptide (Glu1-Lys77) (Figure 1A, Table 1). Kringles 1 and 
4 contain binding sites for lysine residues (LBS, lysine 
binding site) of fibrin that allow interaction and effective 
binding of plasminogen. Kringle 5 contains modified LBS 
with affinity for the lysine residues of the amino-terminal 
peptide that promotes the adoption of a closed spiral con-
formation (Figure 1B).10 This plasminogen closed form 
predominates in the circulation. The release of the amino-
terminal peptide after cleavage by plasmin characterizes a 
truncated open conformation known as Lys-plasminogen. 
An open form also occurs when the LBS is occupied by 
lysine analogues such as epsilon aminocaproic acid (e-
ACA) or tranexamic acid (TXA).11 Indeed, invalidation of 
the LBS function by these molecules prevents interaction 
between the kringle 5 and the amino-terminal peptide. 
Invalidation of the LBS function by these agents also 
prevents binding of plasminogen to fibrin and thus its 
activation by tPA. Surprisingly, it was found that the open 
form (Figure 1B) induced by low doses of EACA is recog-
nized and converted into plasmin by uPA. By homology, 
it is widely accepted that the direct interaction of native 
plasminogen (Glu-plasminogen) with the lysine residues 
of fibrin or membrane glycoproteins leads to a transition 
from the closed form to the open form. This form is ef-
ficiently activated by tPA linked to fibrin or uPA bound to 
its receptor. In summary, the binding of plasminogen to 
fibrin or cell membranes and its transition into the open 
form are necessary conditions for its transformation into 
plasmin by plasminogen activators located nearby. The 
Figure 1. Structure and conformation of plasminogen. 
A. Amino-acids sequence and secondary structure of plasmino-
gen. The 791 amino-acids of Glu-plasminogen (Glu1-Asn791) are 
assembled in structural modules: an aminoterminal (NH2) peptide 
followed by 5 kringle modules (K) and a serine-protease region 
containing the amino acids of the active site (black circles). The 
site of cleavage by the activators (Arg561-Val562) is indicated by the 
open triangle. The cleavage by plasmin at the NH2-terminal peptide 
(Pn/K77, Pn/R68, Pn/K62) results in the truncated form Lys77-Asp791. 
Original figure: http://www.chem.cmu.edu.groups/Llinas/images/
res/res-kringle-PLASMIN.gif
B. The closed form (interaction between the aminoterminal peptide 
and kringle 5) is the main circulating conformation. The open form is 
adopted upon binding of  plasminogen to C-Lys terminal residues of 
fibrin or membrane glycoproteins. Original figure   (Lähteenmäki 
K, Edelman S, Korhonen TK. Trends in Microbiology 2005, 13:79) 
reproduced with permission from Elsevier Limited.
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recent description of the crystal structure of plasminogen 
has confirmed and settled key structure-function relation-
ships among its different constitutive modules.12 
Structure of plasminogen activators 
Both tPA and uPA have as plasminogen, a mosaic structure 
composed of several modules.13 The characteristics of 
these molecules are reported in Table 1. The main func-
tion of the catalytic region of plasminogen activators is 
the conversion of plasminogen to plasmin by cleavage 
of the peptide bond Arg561-Val562. The tPA is secreted by 
endothelial cells as a single-chain protein with a very low 
index of zymogenicity.[2] This indicates that, exception-
ally, the single-chain molecule is as active as the two-chain 
form generated after cleavage of the Arg275-Ile276 of tPA by 
plasmin. However, the adsorption of these two forms of 
tPA onto the surface of fibrin via an interaction between 
the finger module and the D region of fibrin is a sine qua 
non for development of their activity.1,14 
The uPA is released by leukocytes as a classical serine 
protease single-chain zymogen (sc-uPA), which must be 
transformed into a double-chain form (tc-uPA) in order 
to display its full protease activity.[5] The cleavage at 
the peptide bond Lys158-Ile159 of sc-uPA is mainly made 
by plasmin. In contrast, thrombin wipes out the potential 
activity of scu-PA by cleaving it two residues upstream of 
the cleavage site of plasmin.[15] At the NH2-terminal posi-
tion of the uPA is found the EGF module, which contains 
a sequence of interaction for its binding to the receptor 
uPAR. This receptor is itself anchored to the membrane 
via a glycosylphosphatidylinositol group that has a large 
transmembrane mobility. Beyond this function, the uPAR 
in concert with transmembrane glycoproteins activates 
Table 1. Main components of the plasminogen activation system. 
Plasminogen Plasmin suPAR    sc-uPA → tc-uPA tPA
Plasma concentration 0.12- 0.18 mg/mL 0 < 1 ng/mL 3.6 ± 0.9 ng/mL 7.5 ± 2.5 ng/mL
Molar concentration 1.5 to 2 µM 0 < 1.5 pM 50 to 85 pM 70 to 140 pM
Molecular mass 92kDa 84kDa 65kDa 54kDa 70kDa
Cleavage site Arg561-Val562 - - Lys158-Ile159 Arg275-Ile274
Modules P-K1-5-SP K1-5-SP D1-3 EGF-K1-SP F-EGF-K1-2-SP
Polypeptide sequence 1 chain 2 chains 1 chain 1 chain → 2 chains      1 chain / 2 chains
Enzyme activity - ++++ -  +/-  →  ++++          ++++    /     ++++
suPAR: uPAR soluble; P: N-terminal peptide; K: kringle  domaine; SP: serine protease; D: LU (Ly-6 uPAR) module; EGF: epidermal growth 
factor-like module; F: finger module
several intracellular signaling pathways involved in cell 
migration and survival.16 
Plasmin is formed on biological surfaces 
Upon formation of a fibrin clot, plasminogen and tPA bind 
to its surface and acquire the molecular conformation nec-
essary for the composition of an enzyme/substrate complex 
leading to in situ production of plasmin.14 Plasmin formed 
remains bound to fibrin via its LBS and is thus engaged 
exclusively in a fibrinolytic function and protected from 
inhibition by α2-antiplasmin. Indeed, the formation of a 
complex between the catalytic region of plasmin and the 
reactive site of the α2-antiplasmin requires interaction with 
the LBS of kringle 1 of plasmin. Since plasmin remains 
adsorbed to fibrin it can not be inhibited.17  Thus, to this 
surface reaction generating active plasmin can be opposed 
the reaction of inhibition by α2-antiplasmin which takes 
place in the circulation. Lysis of a clot is therefore the result 
of a surface reaction with high specificity from the initial 
formation of plasmin to the acceleration and amplification 
phases of fibrinolysis.  
Molecular interactions on biological surfaces
Plasminogen is immobilized onto lysine residues of fi-
brin via the LBS of kringles 1 and 4. The tPA, although 
having a kringle 2 module with an active LBS, binds to 
fibrin via its finger module. Inded, the affinity of the finger 
module for the D region of fibrin (Kd = 1 nM) is 1000 
times greater than that of kringle 2 for the lysine residue 
(Kd = 1 µM). It is precisely this high affinity interaction 
with fibrin that allows expression of the activity of tPA. 
In the absence of fibrin tPA has only very limited ability 
to activate plasminogen. Conformational changes of plas-
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minogen and tPA after adsorption onto their sites and their 
proximity on the surface of fibrin allow the composition 
of an enzyme/substrate complex resulting in the produc-
tion of plasmin and the lysis of the fibrin polymer. In the 
vascular wall the generation of plasmin at the surface 
of macromolecules of the extracellular matrix follows 
the same principle: plasminogen is immobilized via its 
kringle domains onto fibronectin or laminin where it is 
activated by uPA released by inflammatory cells.5   
On cell membranes, the molecular assembly occurs on 
receptor sites for plasminogen (α-enolase,18 tetrameric 
complex annexin A2-S100A10,[19] histone H2B,[20] or 
the Plg-RKT21) where it is activated by uPA immobilized 
on its receptor uPAR. On certain cells such as endothelial 
cells, smooth muscle cells, or neurons, tPA is attached 
to transmembrane proteins that converts plasminogen 
to plasmin.22,23 In contrast to uPA, no specific or unique 
receptor for tPA has been described.
Acceleration and amplification of fibrinolysis
Plasmin formed in situ can amplify the activation of 
plasminogen by generating new binding sites for plasmi-
nogen.24 Indeed, the first molecules of plasmin generated 
at the fibrin surface, hydrolyze lysyl bridges and unveils 
carboxy-terminal (C-Lys) lysine residues that represent 
new plasminogen binding sites.25 Plasminogen bound to 
C-Lys adopts an open conformation that is recognised and 
activated by tPA bound nearby or by uPA released from 
leukocytes. The uPA does not bind to fibrin but specifi-
cally recognizes the plasminogen bound to C-Lys sites.4 
The increased binding of plasminogen multiplies the 
number of molecules of plasmin formed by the activators 
and enhances the degradation of fibrin and clot lysis. It is 
the multiplication of the number of binding sites of plas-
minogen and the conformational changes thereof which 
are the major factors for the amplification fibrinolysis. 
The transformation of sc-uPA into double-chain uPA is a 
second acceleration factor in the formation of plasmin.26 
Regulation 
The plasminogen activation system is finely regulated by 
(1) serine protease inhibitors (serpins), (2) competitors 
of plasminogen, or (3) by proteolytic remotion of C-Lys 
binding sites.
(1) Serpins. Regulation by serpins directly affects 
plasmin (mainly α2-antiplasmin) or plasminogen activa-
tors (mainly PAI-1). In case of excess tPA or plasmin, 
plasma inhibitors with less restricted specificity can also 
act (α2-macroglobulin, C1 esterase inhibitor).
27 In the cen-
tral nervous system, other inhibitors of the plasminogen 
activation system such as neuroserpin and protease nexin-1 
(PN-1) have been identifie.28, 29 PN-1 also inhibits plasmin 
and thrombin and recent data suggest that PN-1 stored in 
platelets could play an important role in the vascular sys-
tem.30 PAI-2 is produced by the syncytiotrophoblasts and 
monocytes. Its physiopathological role as an inhibitor of 
uPA and tPA remains an enigma, and seems to especially 
have intracellular functions.31 It should be noted that in all 
cases the inhibition of activators or plasmin occurs mainly 
in the circulating or liquid phase and that in generally 
most players in the system of plasminogen activation are 
partially protected form their inhibitors when bound to 
their receptors. 
(2) Competitors. Lipoprotein(a) or Lp(a) may exercise 
antifibrinolytic effect and many studies support the clinical 
relevance of this mechanism in cardiovascular disease.32 
The mechanism antifibrinolytic of this lipoprotein can 
be explained due to its particular structure, a component 
similar to the low density lipoprotein (LDL) and a gly-
coprotein, apo(a) structurally close to plasminogen but 
without enzymatic activity: a non-activatable copy of the 
catalytic region, a copy of the kringle 5 and a variable 
number of copies of the kringle 4 having a high affinity 
for fibrin.[33] Thus, competition between plasminogen 
and apo (a) for fibrin binding limits the amount of bound 
plasminogen, decreases the formation of plasmin and 
inhibits fibrinolysis.34 
(3) Proteolytic remotion of C-Lys binding sites. The 
zymogen TAFI (thrombin-activated fibrinolysis inhibitor; 
procarboxypeptidase U) can be activated by thrombin or 
plasmin in TAFIa.  This exopeptidase cleaves the Lys-C 
residues of proteins, thereby limiting the binding of plas-
minogen to the activation surfaces.35 The in vitro activity 
of TAFIa is well established36 but it does not seem to play 
a role in physiological fibrinolysis in vivo (mouse mode).37 
The important number of  studies supporting  the clinical 
interest for this potential regulator of fibrinolysis, has so 
far provided only associational results.38
Finally, in contrast to the mechanism of regulation of 
plasminogen receptors by TAFIa, agents that block the 
LBS of kringle modules can be used as therapeutic in-
hibitors of the binding of plasminogen. These are lysine 
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analogues such as e-ACA and TXA mentioned above. 
These compounds interact with the LBS of kringle and 
thus block competitively the binding of plasminogen to 
fibrin or cells. Their clinical use as an anti-fibrinolytic 
and anti-haemorrhagic  has recently been discussed in 
several clinico-surgical situations and in a large multi-
center study.39,40 
Functions of the plasminogen activation system
We distinguish the functions of the plasminogen activation 
system (fibrinolysis and pericellular proteolysis) depen-
ding on the nature of the surface on which the reaction 
takes place.
-  Fibrinolysis: cleavage by plasmin of arginyl and lysyl 
bridges of fibrin leading to its dissolution and release 
of degradation products. D-dimer fragments found in 
the circulation reflect both formation of clot and its 
dissolution by plasmin.[1] Efficient fibrinolysis al-
lows recanalization of the occluded vessel. The use 
of thrombolytic agents for the treatment of ischemic 
stroke or coronary events is modeled on this physi-
ological model.
-  Pericellular proteolysis occurs when the formation of 
plasmin occurs at the surface of cell membranes or 
the extracellular matrix.22, 23, 26 At the cellular level, 
plasmin activates transmembrane receptors (PAR, 
protease-activated receptors 1 and 4), induces intra-
cellular signalling41  and a phenotypic response char-
acterized initially by membrane vesiculation.42 The 
released microvesicles bear plasminogen activators 
synthesized by the parent cell.42 The plasmin formed 
in situ induces directly or via the activation of pro-
metalloproteases (MMP-3, 9 and 12) the proteolysis 
of matrix proteins: fibronectin, laminin or vitronec-
tin.43 This proteolysis induces changes in cell adhe-
sion leading to different physiological phenomena 
(cellular remodelling, angiogenesis, cell migration).36 
The plasmin formed in excess or resulting from lack 
of regulators (inhibitors) produces a degradation in 
extenso of the extracellular matrix. This process can 
result in the loss of cell adhesion and death by ap-
optosis as observed in some pathological situations 
(cell death, weakening/rupture of the atherosclerotic 
plaque, aneurysm).44-46 This process of apoptosis 
induced by cell detachment may be thwarted by in-
hibitors such as PAI-1 and protease nexin-1.44-47 It is 
important to differentiate these stages of cell activa-
tion and apoptosis to assess the effects of mediators, 
inhibitors and therapeutic agents.
Fibrinolysis, peculiarities: platelets, microvesicles
The classical pathway of plasminogen activation presented 
above requires the co-assembly of plasminogen and its 
activator (uPA or tPA) on the same surface in order to 
trigger the fibrinolytic or proteolytic process. Moving 
surfaces such as platelets and microvesicles require special 
conditions for the production of plasmin. 
Mechanism of plasminogen binding to platelets
Like other cell membranes, platelets can adsorb plas-
minogen on their surface via C-Lys residues-dependent 
interactions which number is multiplied by 5 on activated 
platelets (specific binding, saturable and reversible).[6] 
This binding is made via the GPIIb / IIIa (αIIb β3) and 
fibrinogen (fibrin) of platelets activated with thrombin.
[48, 49] Plasminogen thus bound adopts an open confor-
mation more easily activated by uPA. Platelets may thus 
contribute to increase the concentration of plasminogen 
and potentially plasmin within the clot despite their pro-
coagulant activity. 
Microvesicles and the plasminogen activation system 
Microvesicles are membrane vesicles released by activated 
cells or cells in apoptosis.[50] Of size between 0.1 and 1μm 
they have exposed phosphatidylserine on their surface, 
contain no DNA fragments and must not be confused with 
apoptotic bodies or exosomes (Figure 2).51 The formation 
and release of microvesicles is the result of an extracellular 
stimulus (physical, chemical or biological) that leads to 
a massive influx of calcium into the cell. The increase in 
intracellular calcium alters the activity of phospholipids 
transporters and stimulates calpains resulting in phosphati-
dylserine externalization, changes in the integrity of the 
cytoskeleton and cell contraction leading to budding of 
microvesicles from the cell membrane.52  Many pathologi-
cal conditions such as cardiovascular disease, diabetes, 
cancer and inflammatory diseases have been associated 
with an increase in the number of microvesicles.53,54
These microvesicles carry on their surface and in their 
cytoplasm proteins of the parent cell. In addition to cell 
type specific clusters of differentiation (CD), various 
biomolecules including tissue factor (TF) and inflamma-
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tory cytokines can be vectorized by microvesicles.55,56 In 
2007, it was shown that microvesicles released from TNF-
stimulated HMEC-1 cells (a cell line that synthesizes uPA 
and its receptor uPAR) with were able to generate plasmin.
[8] Indeed, this type of microvesicles bears at their surface 
uPA / uPAR complexes and uPAR available sites capable 
of binding exogenous uPA (Figure 2). 
The binding of plasminogen to the surface of the 
microvesicles also involves residues C-Lys. A selective 
antibody directed against the α-enolase confirmed that this 
receptor of plasminogen was involved in the binding of 
plasminogen to the surface of endothelial microvesicles. 
Recently it has been also shown that the intracellular 
protein, histone H2B, was involved in the binding of plas-
minogen to the surface of microvesicles.[20] The histone 
H2B is localized to the cell membrane via an interaction 
with phosphatidylserine exposed in the outer leaflet of the 
membrane.[57] Thus, procoagulant phospholipid would 
also increase the number of plasminogen binding sites 
and promote fibrinolysis.
We confirmed the presence of fibrinolytic microvesicles 
in the circulation.[58] [è!] These microvesicles have func-
tional characteristics similar to those previously described 
and bear plasminogen activators synthesized by the pa-
rental cell (leukocytes: uPA, endothelial cells: tPA). These 
findings underscore the pathophysiological relevance that 
such microvesicles could have in vivo.
Figure 2. Plasminogen activation on a microvesicle. 
Representation of a fibrinolytic microvesicle bearing on its surface 
(A) the uPAR receptor anchored to the membrane by the glycos-
ylphosphatidylinositol (GPI) group. (B) conformational change of 
uPAR after binding of sc-uPA. (C) sc-uPA is converted in situ into 
tc-uPA. (D) plasminogen bound to its receptor adopts the open form. 
(E) plasmin generated on the membrane by tc-uPA.
A	new	pathway	of	plasminogen	activation:	fibrinolytic	
cross-talk 
Plasminogen adsorbed to fibrin or to the cell membrane 
adopts the open molecular conformation whose cleavage 
site is easily accessible to activators located nearby on the 
same surface. This is the case of the plasminogen-fibrin-tPA 
ternary complex or of the plasminogen-cell membrane-
uPAR/uPA assembly. However, it was found that uPA in 
solution was an efficient activator of Lys-plasminogen 
and of Glu-plasminogen complexed to e-ACA. These 
observations allowed us to hypothesize the existence of an 
interaction involving two surfaces, one bears plasminogen 
and the other an activator of plasminogen.[9] It was possible 
to show that plasminogen carried by platelets can be recog-
nized by cells or microvesicles bearing the complex uPA/
uPAR. In a similar fashion the plasminogen bound to fibrin 
or matrix proteins can be activated to plasmin by uPA/uPAR 
borne by leukocyte microvesicles. This new mechanism of 
activation of plasminogen that we have called fibrinolytic 
cross-talk (Figure 3) is characteristic of uPA and is therefore 
not sensitive to microvesicles bearing tPA. This specificity 
could be explained by structural arrangements imposed by 
the different modules of tPA (finger-EGF-K1-K2-SP) and 
uPA (EGF-K1-SP) (Table 1). This activation reaction has 
therefore all the characteristics of a specific and saturable 
reaction whose efficiency depends on the number of active 
microvesicles acting on platelets or fibrin. This new acti-
vation pathway may have a role physiologically relevant. 
Indeed, the activation of plasminogen on the surface of 
platelets by microvesicular uPA generates two times more 
plasmin that uPA in solution. Recent studies by independent 
laboratories have confirmed our hypothesis and results.59,61 
Two studies have reported the activation of plasminogen 
bound to fibrin by uPA borne by leukocytes59,61 while the 
third study is focused on the activation of sc-uPA by plasmin 
formed on the platelet surface.60
Relevance	of	the	fibrinolytic	cross-talk	mechanism
This novel mechanism of activation of plasminogen to 
plasmin at the surface of platelets, the extracellular matrix 
and fibrin by uPA raises the question of its involvement in 
different pathophysiological situations:
Fibrinolysis
The binding of plasminogen to platelets during clot for-
mation and the presence of microvesicles bearing uPA 
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Figure 3. Fibrinolytic cross-talk (Blood 2010,  115(10) cover illustration).
In inflammatory processes of the vascular wall, fibrinolysis and proteolysis may be induced via a cross-talk between monocytes or cellular 
microvesicles bearing uPA and platelet-, fibrin-, or extracellular matrix–bound plasminogen. This mechanism of plasmin formation bypasses 
the requirement for co-assembly of plasminogen and uPA on the same surface. See the article by Dejouvencel et al on page 2048. 
The fibrinolytic cross-talk refers to the interaction that is established between two biological surfaces, one carrying plasminogen, the other 
uPA. The surfaces carrying plasminogen (Pg) are represented by the platelet membrane, fibrin or extracellular matrix proteins. The surfaces 
bearing uPA are represented by microvesicles (MVs) issued from leukocytes (MoMV). The microvesicles are moving surfaces, this inter-
surface activation system allows efficient generation of plasmin (Pn) on the surface of fibrin or platelets forming the clot and on proteins of the 
extracellular matrix. Endothelial MVs (EndMV) bear tPA.
would lead to the formation of plasmin and allow the re-
canalisation of an occluded vessel. Indeed, a recent study 
suggests that the activation of plasminogen bound to fibrin 
by leukocytes bearing uPA plays a role in endogenous 
fibrinolysis.61
Cell migration and angiogenesis
Aside from its fibrinolytic function, plasmin formation by 
the uPA/uPAR system is involved in tissue remodelling 
via the activation of proMMP and plays a critical role in 
cell migration and angiogenesis.[16] Indeed, vascular 
regeneration involves both angiogenesis and vasculogen-
esis-dependent endothelial progenitor cells. The ability of 
endothelial microvesicles to generate plasmin influences 
and modulates the repair process of endothelial progenitor 
cells. A small amount of microvesicles bearing an active 
plasminogen activation system, promotes cell migration 
and angiogenesis whereas at high concentrations the ex-
cess plasmin leads to matrix degradation, decreased cell 
adhesiveness and finally apoptosis.8,35
Dissemination of cancer cells 
The spread of cancer cells is a consequence of matrix deg-
radation and loss of cell adhesion. High amounts of uPA/
uPAR were associated with advanced metastatic cancers.62 
It is interesting to note that the described fibrinolytic/
proteolytic cross-talk mechanism is only possible in the 
presence of an activator of the uPA-type. This activa-
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tor is involved in tumour progression and was found on 
microvesicles emitted by cancerous cells. In addition, mi-
crovesicles released by platelets may promote metastasis 
and promote angiogenesis.63 
Conclusion and potential applications
The structure and function of molecules of the plasmi-
nogen activation system including the recent description 
of the crystal structure of plasminogen,12 and their role 
in the maintenance of haemostasis and thrombosis pre-
vention is now well established. However, detection of 
a dysfunction of this system remains a major challenge 
for the haematologist and the vascular biologist. The 
circulating concentration of plasminogen activators is ex-
tremely low compared to active concentrations required 
at the site of injury in the microcirculation. Moreover, the 
plasminogen activators circulate as an inactive complex 
with PAI-1 and only the forms located on the cell mem-
brane (uPA, tPA) or fibrin (tPA) are active. Furthermore, 
since all measurements performed in plasma do not take 
into account the contribution of cellular activators, it is 
therefore impossible to quantify a lack of tPA or uPA 
activity that may be the cause of a fibrinolytic default. 
The recent discovery of cellular fibrinolytic microvesicles 
and a new mechanism for the formation of plasmin, the fi-
brinolytic cross-talk, opened up new perspectives.8 These 
microvesicles would act within the clot, thus explaining 
the lack of systemic fibrinolysis as demonstrated in vivo 
in a mouse model of fibrinolytic platelets.64 We suggest 
that the fibrinolytic activity of endothelial and leukocyte 
microvesicles compensates locally the activity of proco-
agulant microvesicles. Is this phenomenon that explains 
the spontaneous re-canalization observed in 10-20% of 
patients with acute occlusion of the coronary arteries?65,66 
Accordingly, the functional balance between these two 
types of microvesicles would result in a physiological 
haemostatic response, while the lack of fibrinolytic mi-
crovesicles may promote the formation of a thrombus. 
The existence of a haemorrhagic syndrome (Quebec 
platelet disorder) caused by profibrinolytic platelets 
having an abnormal expression of uPA is consistent with 
this hypothesis.67 Using a mouse model of this autosomal 
dominant disease it was possible to demonstrate that 
these animals are resistant to arterial thrombosis and that 
transfusion of these platelets to control mice prevent the 
formation of occlusive arterial thrombi.67 
In this context, the presence of plasminogen and its 
activator uPA or tPA on moving surfaces (respectively 
platelets and microvesicles) and the identification of the 
fibrinolytic cross-talk mechanism suggests the possibil-
ity of using these materials as vectors of fibrinolysis and 
pericellular proteolysis. 
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